Printer Friendly

CYGNUS SHIPS ITS NICOTINE PATCH

 CYGNUS SHIPS ITS NICOTINE PATCH
 REDWOOD CITY, Calif., July 6 /PRNewswire/ -- Cygnus Therapeutic


Systems (NASDAQ: CYGN), a leader in transdermal drug delivery, announced today that it began shipping its nicotine transdermal product, Nicotrol(TM) at the end of June.
 "The nicotine patch was specifically developed for use during 'waking hours,'" said Dr. Gregory B. Lawless, president and chief executive officer. "FDA approval was received in April and Cygnus has manufactured initial launch quantities to support the product's introduction in the U.S. by Warner-Lambert."
 According to Dr. David Sachs, director of the Palo Alto Center for Pulmonary Disease Prevention, "In my large-scale clinical study with the Cygnus patch, we found that patients wore it an average of 16 hours per day, and I was pleased to see very little systemic side effects such as sleep disruption, or abnormal dreams, or any heart problems. There was only minimal and easily tolerated skin irritation. My clinical trial showed this to be a safe and very well-tolerated nicotine patch," Sachs concluded. Sachs is a leading clinical researcher who has been involved in the area of smoking cessation since 1975.
 "Nicotrol is entering a market which had sales in excess of $200 million in the first quarter of 1992," Lawless said. "Demand has been greater than expected leaving nicotine patch manufacturers unable to produce sufficient quantities of product, and some pharmacies were not able to fill prescriptions."
 The inability to supply has resulted in a "lack of brand loyalty in the nicotine patch market that should work to the benefit of Nicotrol," according to D. Larry Smith's report.
 Nicotrol will be marketed in North America by Parke-Davis, a division of the Warner-Lambert Co., as part of a comprehensive behavioral smoking cessation program. It will be manufactured by Cygnus, and in the rest of the world, will be marketed by Kabi Pharmacia A.B. of Sweden under the trade name Nicorette(TM). Nicorette is already an established trademark in smoking cessation through Nicorette gum. Approval for the product has been granted in Italy and Sweden, and is expected in several European countries this year.
 Cygnus is a leader and innovator in the development of advanced transdermal drug delivery systems, and is located at its Redwood City headquarters. In addition to Nicotrol, the company has two other products in advanced clinical trials: an estradiol patch that is used for the treatment of the symptoms of menopause and the prevention of osteoporosis, and a fentanyl patch for moderate to severe post-operative pain management. Cygnus Therapeutic Systems has 11 U.S. patents issued or allowed and over 300 patent applications worldwide covering its transdermal technology.
 -0- 7/6/92
 /CONTACT: Shirley Clayton of Cygnus, 415-599-3552; or Susan Atkins of Susan Atkins PR, 415-921-5929, for Cygnus/
 (CYGN) CO: Cygnus Therapeutic Systems Inc. ST: California IN: MTC SU: PDT


MM-MC -- SF009X -- 6801 07/06/92 18:18 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 6, 1992
Words:478
Previous Article:CYGNUS SHIPS ITS NICOTINE PATCH
Next Article:SOUTHWESTERN BELL ADDS TWO NEW VIDEO SERVICES; OFFERINGS BRING ECONOMY, FLEXIBILITY TO BUSINESSES
Topics:


Related Articles
CYGNUS ANNOUNCES NEW SCIENTIFIC AFFAIRS VP FORMERLY WITH CHIRON, BEECHAM, SYNTEX IN SENIOR REGULATORY POSITIONS
MOST NICOTINE PATCH USERS DOOMED TO FAIL
LECTEC RESPONDS TO FDA ADVISORY PANEL INVESTIGATING REPORTS OF ADVERSE REACTIONS OF NICOTINE PATCHES
WARNER-LAMBERT LAUNCHES MAJOR SMOKING CESSATION INITIATIVE; WELLNESS PROGRAM WILL ASSIST EMPLOYEES IN COPING WITH SMOKING RESTRICTIONS
NICOTINE PATCH AGREEMENT SIGNED
CYGNUS' NICOTROL(R) RECEIVES FDA ADVISORY PANEL RECOMMENDATION FOR OVER-THE-COUNTER SALE
THE FOOD AND DRUG ADMINISTRATION APPROVES SMITHKLINE BEECHAM'S NICODERM CQ FOR OVER-THE-COUNTER USE
SmithKline Beecham's NicoDerm CQ Now Available in Stores: Number One Prescription Nicotine Patch Available Over-the-Counter
Cygnus Reports Third Quarter Results
Sano Corporation Reports Positive Results From Phase II Trial Of New Therapeutic For Smoking Cessation

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters